|
1
|
Stupp R, Taillibert S, Kanner AA, Kesari
S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink
KL, et al: Maintenance therapy with tumor-treating fields plus
temozolomide vs temozolomide alone for glioblastoma: A randomized
clinical trial. JAMA. 314:2535–2543. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu R, Wang X, Chen GY, Dalerba P, Gurney
A, Hoey T, Sherlock G, Lewicki J, Shedden K and Clarke MF: The
prognostic role of a gene signature from tumorigenic breast-cancer
cells. N Engl J Med. 356:217–226. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Duncan JS and Litchfield DW: Too much of a
good thing: The role of protein kinase CK2 in tumorigenesis and
prospects for therapeutic inhibition of CK2. Biochim Biophys Acta.
1784:33–47. 2008. View Article : Google Scholar
|
|
4
|
Kroonen J, Artesi M, Capraro V,
Nguyen-Khac MT, Willems M, Chakravarti A, Bours V and Robe PA:
Casein kinase 2 inhibition modulates the DNA damage response but
fails to radiosensitize malignant glioma cells. Int J Oncol.
41:776–782. 2012.PubMed/NCBI
|
|
5
|
Mandal T, Bhowmik A, Chatterjee A,
Chatterjee U, Chatterjee S and Ghosh MK: Reduced phosphorylation of
Stat3 at Ser-727 mediated by casein kinase 2 - protein phosphatase
2A enhances Stat3 Tyr-705 induced tumorigenic potential of glioma
cells. Cell Signal. 26:1725–1734. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Romieu-Mourez R, Landesman-Bollag E,
Seldin DC, Traish AM, Mercurio F and Sonenshein GE: Roles of IKK
kinases and CK2 in activation of NFκB in breast cancer. Cancer Res.
61:3810–3818. 2001.PubMed/NCBI
|
|
7
|
Turowec JP, Vilk G, Gabriel M and
Litchfield DW: Characterizing the convergence of protein kinase CK2
and caspase-3 reveals isoform-specific phosphorylation of caspase-3
by CK2α': Implications for pathological roles of CK2 in promoting
cancer cell survival. Oncotarget. 4:560–571. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nitta RT, Gholamin S, Feroze AH, Agarwal
M, Cheshier SH, Mitra SS and Li G: Casein kinase 2α regulates
glioblastoma brain tumor-initiating cell growth through the
β-catenin pathway. Oncogene. 34:3688–3699. 2015. View Article : Google Scholar :
|
|
9
|
Zheng Y, McFarland BC, Drygin D, Yu H,
Bellis SL, Kim H, Bredel M and Benveniste EN: Targeting protein
kinase CK2 suppresses prosurvival signaling pathways and growth of
glioblastoma. Clin Cancer Res. 19:6484–6494. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Verhaak RGW, Hoadley KA, Purdom E, Wang V,
Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al;
Cancer Genome Atlas Research Network. Integrated genomic analysis
identifies clinically relevant subtypes of glioblastoma
characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Romieu-Mourez R, Landesman-Bollag E,
Seldin DC and Sonenshein GE: Protein kinase CK2 promotes aberrant
activation of nuclear factor-kappaB, transformed phenotype, and
survival of breast cancer cells. Cancer Res. 62:6770–6778.
2002.PubMed/NCBI
|
|
12
|
Guerra B, Iwabuchi K and Issinger O-G:
Protein kinase CK2 is required for the recruitment of 53BP1 to
sites of DNA double-strand break induced by radiomimetic drugs.
Cancer Lett. 345:115–123. 2014. View Article : Google Scholar
|
|
13
|
Olsen BB, Fritz G and Issinger O-G:
Characterization of ATM and DNA-PK wild-type and mutant cell lines
upon DSB induction in the presence and absence of CK2 inhibitors.
Int J Oncol. 40:592–598. 2012.
|
|
14
|
Dixit D, Sharma V, Ghosh S, Mehta VS and
Sen E: Inhibition of Casein kinase-2 induces p53-dependent cell
cycle arrest and sensitizes glioblastoma cells to tumor necrosis
factor (TNFα)-induced apoptosis through SIRT1 inhibition. Cell
Death Dis. 3:e2712012. View Article : Google Scholar
|
|
15
|
Berendsen S, Varkila M, Kroonen J, Seute
T, Snijders TJ, Kauw F, Spliet WG, Willems M, Poulet C, Broekman
ML, et al: Prognostic relevance of epilepsy at presentation in
glioblastoma patients. Neuro Oncol. Sep 29–2015.(Epub ahead of
print]). PubMed/NCBI
|
|
16
|
Robe PA, Bentires-Alj M, Bonif M, Rogister
B, Deprez M, Haddada H, Khac MT, Jolois O, Erkmen K, Merville MP,
et al: In vitro and in vivo activity of the nuclear factor-kappaB
inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res.
10:5595–5603. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shen J, Channavajhala P, Seldin DC and
Sonenshein GE: Phosphorylation by the protein kinase CK2 promotes
calpain-mediated degradation of IkappaBalpha. J Immunol.
167:4919–4925. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Robe PA, Nguyen-Khac M-T, Lambert F,
Lechanteur C, Jolois O, Ernst-Gengoux P, Rogister B and Bours V:
Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene
therapy bystander effect in malignant gliomas. Int J Oncol.
30:283–290. 2007.
|
|
19
|
Bredel M, Bredel C, Juric D, Duran GE, Yu
RX, Harsh GR, Vogel H, Recht LD, Scheck AC and Sikic BI: Tumor
necrosis factor-alpha-induced protein 3 as a putative regulator of
nuclear factor-kappaB-mediated resistance to O6-alkylating agents
in human glioblastomas. J Clin Oncol. 24:274–287. 2006. View Article : Google Scholar
|
|
20
|
Artesi M, Kroonen J, Bredel M, Nguyen-Khac
M, Deprez M, Schoysman L, Poulet C, Chakravarti A, Kim H, Scholtens
D, et al: Connexin 30 expression inhibits growth of human malignant
gliomas but protects them against radiation therapy. Neuro-oncol.
17:392–406. 2015.
|
|
21
|
Robe PA, Rogister B, Merville M-P and
Bours V: Growth regulation of astrocytes and C6 cells by TGFbeta1:
Correlation with gap junctions. Neuroreport. 11:2837–2841. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Goffart N, Kroonen J and Rogister B:
Glioblastoma-initiating cells: Relationship with neural stem cells
and the micro-environment. Cancers (Basel). 5:1049–1071. 2013.
View Article : Google Scholar
|
|
23
|
Kore RA and Abraham EC: Inflammatory
cytokines, interleukin-1 beta and tumor necrosis factor-alpha,
upregulated in glioblastoma multiforme, raise the levels of CRYAB
in exosomes secreted by U373 glioma cells. Biochem Biophys Res
Commun. 453:326–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bredel M, Scholtens DM, Yadav AK, Alvarez
AA, Renfrow JJ, Chandler JP, Yu IL, Carro MS, Dai F, Tagge MJ, et
al: NFKBIA deletion in glioblastomas. N Engl J Med. 364:627–637.
2011. View Article : Google Scholar
|
|
25
|
Yu M, Yeh J and Van Waes C: Protein kinase
casein kinase 2 mediates inhibitor-kappaB kinase and aberrant
nuclear factor-kappaB activation by serum factor(s) in head and
neck squamous carcinoma cells. Cancer Res. 66:6722–6731. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo S, Demicco EG, Romieu-Mourez R,
Landesman-Bollag E, Seldin DC and Sonenshein GE: Inducible IκB
kinase/IκB kinase ɛ expression is induced by CK2 and promotes
aberrant nuclear factor-κB activation in breast cancer cells.
Cancer Res. 65:11375–11383. 2005. View Article : Google Scholar
|
